LH
$323.73+0.19%
as of close, Oct 21, 2026
☾ AH $323.73 +0.19%
LH SEC filings (2026)
CIK 920148 · Services-Medical Laboratories (SIC 8071) · fiscal year ends in December
3,890 filings on EDGAR since 1994 · 39 annual, 100 quarterly, 1,110 current · financial statements · earnings
Latest 10-K
Feb 24, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Aug 5, 2026
quarter to Jun 30, 2026
Latest 8-K
Sep 30, 2026
Labcorp to Announce Third Quarter Financial Results on October 28, 2026
Last earnings release
Jul 30, 2026
$4.99 vs $4.79 · ▲ 2.7%
Filings on file
3,890
since 1994, 2,180 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
September 2026
- Sep 308-K8-K · Labcorp to Announce Third Quarter Financial Results on October 28, 2026Regulation FD disclosure
- Sep 228-K8-K · Regulation FD disclosure
- Sep 108-K8-K · Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor DayRegulation FD disclosure
August 2026
- Aug 288-K8-K · Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare ConferenceRegulation FD disclosure
- Aug 17Insider saleANDERSON KERRII B (Director) sold 3,000 shares for $954K at $318.02 under a 10b5-1 plan
- Aug 178-K8-K · Labcorp to Host Investor Day on September 10, 2026Regulation FD disclosure
- Aug 148-K8-K · Directors or officers; compensation
- Aug 11Insider saleSchechter Adam H (President & CEO · Director) sold 4,669 shares for $1.5M at $320.37 under a 10b5-1 plan
- Aug 5ReportQuarterly report, Q2 2026 — revenue $3.73B (+6% y/y), net income $298.7M, EPS $3.64
- Aug 4Insider saleSummy Amy B. (EVP, Chief Marketing Officer) sold 924 shares for $283K at $306.74
- Aug 3Insider saleWilkinson Peter J (SVP, Chief Accounting Officer) sold 1,420 shares for $439K at $309.22–$309.23
July 2026
- Jul 30EarningsEarnings release — EPS $4.99 vs $4.79 est. (+4.2%); revenue $3.73B (+6% y/y) 2.7%
- Jul 108-K8-K · Labcorp Declares Quarterly DividendRegulation FD disclosure
- Jul 2Insider saleVaughn Bryan T (EVP and President, Diagnostics) sold 234 shares for $67K at $286.19 under a 10b5-1 plan
- Jul 2Insider saleKyle Kathryn W (EVP, Chief Legal Officer) sold 92 shares for $26K at $286.19 under a 10b5-1 plan
June 2026
- Jun 308-K8-K · Labcorp to Announce Second Quarter Financial Results on July 30, 2026Regulation FD disclosure
- Jun 8Insider saleKyle Kathryn W (EVP, Chief Legal Officer) sold 762 shares for $201K at $263.89 under a 10b5-1 plan
May 2026
- May 278-K8-K · Labcorp to Present at the Jefferies Global Healthcare ConferenceRegulation FD disclosure
- May 268-K8-K · Shareholder vote results
- May 11Insider saleSchechter Adam H (President & CEO · Director) sold 5,903 shares for $1.5M at $254.50 under a 10b5-1 plan
- May 4ReportQuarterly report, Q1 2026 — revenue $3.54B (+6% y/y), net income $277.8M, EPS $3.35
April 2026
- Apr 30EarningsEarnings release — EPS $4.25 vs $4.09 est. (+3.9%); revenue $3.54B (+6% y/y) 0.1%
- Apr 10ProxyProxy · Annual report to shareholders
- Apr 10ProxyProxy · Additional proxy materials
- Apr 10ProxyProxy · Proxy statement
- Apr 98-K8-K · Labcorp Declares Quarterly DividendRegulation FD disclosure
March 2026
- Mar 318-K8-K · Labcorp to Announce First Quarter Financial Results on April 30, 2026Regulation FD disclosure
- Mar 27Insider saleWilkinson Peter J (SVP, Chief Accounting Officer) sold 1,633 shares for $436K at $267.05 under a 10b5-1 plan
- Mar 27Insider saleMeltzer Jonathan C (EVP, Operations) sold 839 shares for $224K at $267.05 under a 10b5-1 plan
- Mar 208-K8-K · Material definitive agreement; New financial obligation
- Mar 3Insider saleSchechter Adam H (President & CEO · Director) sold 8,705 shares for $2.4M at $279.96
February 2026
- Feb 27Insider salevan der Vaart Sandra D (EVP, Corporate Affairs) sold 547.54 shares for $156K at $284.91
- Feb 24ReportAnnual report, FY2025 — revenue $13.95B (+7% y/y), net income $876.5M, EPS $10.46
- Feb 24Insider saleCaveney Brian J (EVP, Pres of ED, CMO & CSO) sold 1,500 shares for $429K at $286.31
- Feb 19Insider saleWilkinson Peter J (SVP, Chief Accounting Officer) sold 666 shares for $185K at $277.94 under a 10b5-1 plan
- Feb 17EarningsEarnings release — EPS $4.07 vs $3.95 est. (+3.0%); revenue $3.52B (+6% y/y) 2.1%
- Feb 12Insider saleMeltzer Jonathan C (EVP, Operations) sold 87 shares for $25K at $290.42 under a 10b5-1 plan
- Feb 11Insider saleSchechter Adam H (President & CEO · Director) sold 5,273 shares for $1.5M at $284.38 under a 10b5-1 plan
- Feb 10Insider saleMeltzer Jonathan C (EVP, Operations) sold 91 shares for $25K at $276.79 under a 10b5-1 plan
- Feb 9Insider saleMeltzer Jonathan C (EVP, Operations) sold 88 shares for $24K at $275.53 under a 10b5-1 plan
- Feb 98-K8-K · Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of DirectorsDirectors or officers; compensation; Regulation FD disclosure
January 2026
- Jan 298-K8-K · Material definitive agreement; New financial obligation
- Jan 158-K8-K · Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026Regulation FD disclosure
- Jan 148-K8-K · Labcorp Declares Quarterly DividendRegulation FD disclosure
December 2025
- Dec 308-K8-K · Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare ConferenceRegulation FD disclosure
- Dec 158-K8-K · Directors or officers; compensation
- Dec 108-K8-K · Labcorp Announces Retirement of Dr. D. Gary Gilliland from its Board of DirectorsDirectors or officers; compensation; Regulation FD disclosure
November 2025
October 2025
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $10.4M in 18 sales and bought nothing on the open market; 198 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Aug 17, 2026Form 4 | ANDERSON KERRII BDirectorSold · $954K · 3,000 sh · 10b5-1 |
| Aug 11, 2026Form 4 | Schechter Adam HPresident & CEO · DirectorSold · $1.5M · 4,669 sh · 10b5-1 |
| Aug 4, 2026Form 4 | Summy Amy B.EVP, Chief Marketing OfficerSold · $283K · 924 sh |
| Aug 3, 2026Form 4 | Wilkinson Peter JSVP, Chief Accounting OfficerSold · $439K · 1,420 sh |
| Jul 2, 2026Form 4 | Vaughn Bryan TEVP and President, DiagnosticsSold · $67K · 234 sh · 10b5-1 |
| Jul 2, 2026Form 4 | Kyle Kathryn WEVP, Chief Legal OfficerSold · $26K · 92 sh · 10b5-1 |
| Jun 8, 2026Form 4 | Kyle Kathryn WEVP, Chief Legal OfficerSold · $201K · 762 sh · 10b5-1 |
| May 11, 2026Form 4 | Schechter Adam HPresident & CEO · DirectorSold · $1.5M · 5,903 sh · 10b5-1 |
| Mar 27, 2026Form 4 | Wilkinson Peter JSVP, Chief Accounting OfficerSold · $436K · 1,633 sh · 10b5-1 |
| Mar 27, 2026Form 4 | Meltzer Jonathan CEVP, OperationsSold · $224K · 839 sh · 10b5-1 |
| Mar 3, 2026Form 4 | Schechter Adam HPresident & CEO · DirectorSold · $2.4M · 8,705 sh |
| Feb 27, 2026Form 4 | van der Vaart Sandra DEVP, Corporate AffairsSold · $156K · 547.54 sh |
| Feb 24, 2026Form 4 | Caveney Brian JEVP, Pres of ED, CMO & CSOSold · $429K · 1,500 sh |
| Feb 19, 2026Form 4 | Wilkinson Peter JSVP, Chief Accounting OfficerSold · $185K · 666 sh · 10b5-1 |
| Feb 12, 2026Form 4 | Meltzer Jonathan CEVP, OperationsSold · $25K · 87 sh · 10b5-1 |
| Feb 11, 2026Form 4 | Schechter Adam HPresident & CEO · DirectorSold · $1.5M · 5,273 sh · 10b5-1 |
| Feb 10, 2026Form 4 | Meltzer Jonathan CEVP, OperationsSold · $25K · 91 sh · 10b5-1 |
| Feb 9, 2026Form 4 | Meltzer Jonathan CEVP, OperationsSold · $24K · 88 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 198 transactions
| Date | Insider |
|---|---|
| Sep 1, 2026Form 4 | Caveney Brian JEVP, Pres of BLS, CMO & CSOAward · Restricted Stock Unit · $0 · 3,000 sh |
| Sep 1, 2026Form 4 | Vaughn Bryan TEVP and President, DiagnosticsAward · Restricted Stock Unit · $0 · 1,500 sh |
| Sep 1, 2026Form 4 | Meltzer Jonathan CEVP, COOAward · Restricted Stock Unit · $0 · 900 sh |
| Sep 1, 2026Form 4 | Oyegunwa AkinboladeEVP, CIO & CTOAward · Restricted Stock Unit · $0 · 750 sh |
| Aug 3, 2026Form 4 | Wilkinson Peter JSVP, Chief Accounting OfficerExercise or conversion · $280K · 1,338 sh |
| Aug 3, 2026Form 4 | Wilkinson Peter JSVP, Chief Accounting OfficerExercise or conversion · Non-qualified Stock Options · $0 · 1,338 sh |
| Jul 1, 2026Form 4 | Vaughn Bryan TEVP and President, DiagnosticsTax withholding · $26K · 93 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Kyle Kathryn WEVP, Chief Legal OfficerTax withholding · $21K · 73 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Vaughn Bryan TEVP and President, DiagnosticsExercise or conversion · — · 327 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Vaughn Bryan TEVP and President, DiagnosticsExercise or conversion · Restricted Stock Unit · $0 · 327 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Kyle Kathryn WEVP, Chief Legal OfficerExercise or conversion · — · 256 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Kyle Kathryn WEVP, Chief Legal OfficerExercise or conversion · Restricted Stock Unit · $0 · 256 sh · 10b5-1 |
| Mar 26, 2026Form 4 | Schechter Adam HPresident & CEO · DirectorTax withholding · $7.0M · 26,106 sh |
| Mar 26, 2026Form 4 | Schroeder Mark SEVP, Pres Diagnostics & COOTax withholding · $1.6M · 6,068 sh |
| Mar 26, 2026Form 4 | Caveney Brian JEVP, Pres of ED, CMO & CSOTax withholding · $1.3M · 4,905 sh |
| Mar 26, 2026Form 4 | GRAHAM ANITA ZEVP, CHROTax withholding · $773K · 2,879 sh |
| Mar 26, 2026Form 4 | van der Vaart Sandra DEVP, Corporate AffairsTax withholding · $731K · 2,722 sh |
| Mar 26, 2026Form 4 | Summy Amy B.EVP, Chief Marketing OfficerTax withholding · $493K · 1,836 sh |
| Mar 26, 2026Form 4 | Wilkinson Peter JSVP, Chief Accounting OfficerTax withholding · $203K · 755 sh · 10b5-1 |
| Mar 26, 2026Form 4 | Meltzer Jonathan CEVP, OperationsTax withholding · $191K · 711 sh · 10b5-1 |
| Mar 26, 2026Form 4 | Bailey Megan D.EVP, Pres, Central Labs & IntlTax withholding · $129K · 481 sh |
| Mar 26, 2026Form 4 | Kyle Kathryn WEVP, Chief Legal OfficerTax withholding · $121K · 451 sh |
| Mar 26, 2026Form 4 | Vaughn Bryan TEVP, DiagnosticsTax withholding · $121K · 451 sh |
| Mar 26, 2026Form 4 | Oyegunwa AkinboladeEVP, CIO & CTOTax withholding · $103K · 382 sh |
| Mar 26, 2026Form 4 | Schechter Adam HPresident & CEO · DirectorAward · $0 · 58,470 sh |
| Mar 26, 2026Form 4 | Schroeder Mark SEVP, Pres Diagnostics & COOAward · $0 · 12,272 sh |
| Mar 26, 2026Form 4 | Caveney Brian JEVP, Pres of ED, CMO & CSOAward · $0 · 11,290 sh |
| Mar 26, 2026Form 4 | GRAHAM ANITA ZEVP, CHROAward · $0 · 6,604 sh |
| Mar 26, 2026Form 4 | van der Vaart Sandra DEVP, Corporate AffairsAward · $0 · 6,382 sh |
| Mar 26, 2026Form 4 | Summy Amy B.EVP, Chief Marketing OfficerAward · $0 · 3,994 sh |
| Mar 26, 2026Form 4 | Meltzer Jonathan CEVP, OperationsAward · $0 · 2,388 sh · 10b5-1 |
| Mar 26, 2026Form 4 | Wilkinson Peter JSVP, Chief Accounting OfficerAward · $0 · 2,388 sh · 10b5-1 |
| Mar 26, 2026Form 4 | Kyle Kathryn WEVP, Chief Legal OfficerAward · $0 · 1,584 sh |
| Mar 26, 2026Form 4 | Vaughn Bryan TEVP, DiagnosticsAward · $0 · 1,584 sh |
| Mar 26, 2026Form 4 | Oyegunwa AkinboladeEVP, CIO & CTOAward · $0 · 1,340 sh |
| Mar 26, 2026Form 4 | Bailey Megan D.EVP, Pres, Central Labs & IntlAward · $0 · 1,184 sh |
| Feb 11, 2026Form 4 | Schechter Adam HPresident & CEO · DirectorTax withholding · $441K · 1,521 sh · 10b5-1 |
| Feb 11, 2026Form 4 | Schroeder Mark SEVP, Pres Diagnostics & COOTax withholding · $75K · 259 sh |
| Feb 11, 2026Form 4 | Wang Julia AijunChief Financial Officer, EVPTax withholding · $71K · 245 sh |
| Feb 11, 2026Form 4 | Caveney Brian JEVP, Pres of ED, CMO & CSOTax withholding · $61K · 211 sh |
| Feb 11, 2026Form 4 | Wilkinson Peter JSVP, Chief Accounting OfficerTax withholding · $60K · 206 sh |
| Feb 11, 2026Form 4 | Bailey Megan D.EVP, Pres, Central Labs & IntlTax withholding · $40K · 138 sh |
| Feb 11, 2026Form 4 | GRAHAM ANITA ZEVP, CHROTax withholding · $32K · 109 sh |
| Feb 11, 2026Form 4 | van der Vaart Sandra DEVP, Corporate AffairsTax withholding · $29K · 99 sh |
| Feb 11, 2026Form 4 | Vaughn Bryan TEVP, DiagnosticsTax withholding · $27K · 93 sh |
| Feb 11, 2026Form 4 | Summy Amy B.EVP, Chief Marketing OfficerTax withholding · $24K · 83 sh |
| Feb 11, 2026Form 4 | Meltzer Jonathan CEVP, OperationsTax withholding · $20K · 70 sh · 10b5-1 |
| Feb 11, 2026Form 4 | Oyegunwa AkinboladeEVP, CIO & CTOTax withholding · $20K · 68 sh |
| Feb 11, 2026Form 4 | Kyle Kathryn WEVP, Chief Legal OfficerTax withholding · $18K · 62 sh |
| Feb 11, 2026Form 4 | Schechter Adam HPresident & CEO · DirectorExercise or conversion · — · 3,656 sh · 10b5-1 |
| Feb 11, 2026Form 4 | Schechter Adam HPresident & CEO · DirectorExercise or conversion · Restricted Stock Unit · $0 · 3,656 sh · 10b5-1 |
| Feb 11, 2026Form 4 | ANDERSON KERRII BDirectorExercise or conversion · — · 897 sh |
| Feb 11, 2026Form 4 | ANDERSON KERRII BDirectorExercise or conversion · Restricted Stock Unit · $0 · 897 sh |
| Feb 11, 2026Form 4 | Davis Jeffrey A.DirectorExercise or conversion · — · 897 sh |
| Feb 11, 2026Form 4 | Davis Jeffrey A.DirectorExercise or conversion · Restricted Stock Unit · $0 · 897 sh |
| Feb 11, 2026Form 4 | Kliphouse Kirsten MarieDirectorExercise or conversion · — · 897 sh |
| Feb 11, 2026Form 4 | Kliphouse Kirsten MarieDirectorExercise or conversion · Restricted Stock Unit · $0 · 897 sh |
| Feb 11, 2026Form 4 | Kong GarhengDirectorExercise or conversion · — · 897 sh |
| Feb 11, 2026Form 4 | Kong GarhengDirectorExercise or conversion · Restricted Stock Unit · $0 · 897 sh |
| Feb 11, 2026Form 4 | NEUPERT PETER MDirectorExercise or conversion · — · 897 sh |
| Feb 11, 2026Form 4 | NEUPERT PETER MDirectorExercise or conversion · Restricted Stock Unit · $0 · 897 sh |
| Feb 11, 2026Form 4 | Parham Richelle PDirectorExercise or conversion · — · 897 sh |
| Feb 11, 2026Form 4 | Parham Richelle PDirectorExercise or conversion · Restricted Stock Unit · $0 · 897 sh |
| Feb 11, 2026Form 4 | Wengel Kathryn EDirectorExercise or conversion · — · 897 sh |
| Feb 11, 2026Form 4 | Wengel Kathryn EDirectorExercise or conversion · Restricted Stock Unit · $0 · 897 sh |
| Feb 11, 2026Form 4 | Rothman PaulDirectorExercise or conversion · — · 897 sh |
| Feb 11, 2026Form 4 | Rothman PaulDirectorExercise or conversion · Restricted Stock Unit · $0 · 897 sh |
| Feb 11, 2026Form 4 | Wang Julia AijunChief Financial Officer, EVPExercise or conversion · — · 860 sh |
| Feb 11, 2026Form 4 | Wang Julia AijunChief Financial Officer, EVPExercise or conversion · Restricted Stock Unit · $0 · 860 sh |
| Feb 11, 2026Form 4 | Schroeder Mark SEVP, Pres Diagnostics & COOExercise or conversion · — · 806 sh |
| Feb 11, 2026Form 4 | Schroeder Mark SEVP, Pres Diagnostics & COOExercise or conversion · Restricted Stock Unit · $0 · 806 sh |
| Feb 11, 2026Form 4 | Caveney Brian JEVP, Pres of ED, CMO & CSOExercise or conversion · — · 740 sh |
| Feb 11, 2026Form 4 | Caveney Brian JEVP, Pres of ED, CMO & CSOExercise or conversion · Restricted Stock Unit · $0 · 740 sh |
| Feb 11, 2026Form 4 | Wilkinson Peter JSVP, Chief Accounting OfficerExercise or conversion · — · 696 sh |
| Feb 11, 2026Form 4 | Wilkinson Peter JSVP, Chief Accounting OfficerExercise or conversion · Restricted Stock Unit · $0 · 696 sh |
| Feb 11, 2026Form 4 | Bailey Megan D.EVP, Pres, Central Labs & IntlExercise or conversion · — · 403 sh |
| Feb 11, 2026Form 4 | Bailey Megan D.EVP, Pres, Central Labs & IntlExercise or conversion · Restricted Stock Unit · $0 · 403 sh |
| Feb 11, 2026Form 4 | van der Vaart Sandra DEVP, Corporate AffairsExercise or conversion · — · 376 sh |
| Feb 11, 2026Form 4 | van der Vaart Sandra DEVP, Corporate AffairsExercise or conversion · Restricted Stock Unit · $0 · 376 sh |
| Feb 11, 2026Form 4 | GRAHAM ANITA ZEVP, CHROExercise or conversion · — · 356 sh |
| Feb 11, 2026Form 4 | GRAHAM ANITA ZEVP, CHROExercise or conversion · Restricted Stock Unit · $0 · 356 sh |
| Feb 11, 2026Form 4 | Vaughn Bryan TEVP, DiagnosticsExercise or conversion · — · 323 sh |
| Feb 11, 2026Form 4 | Vaughn Bryan TEVP, DiagnosticsExercise or conversion · Restricted Stock Unit · $0 · 323 sh |
| Feb 11, 2026Form 4 | Meltzer Jonathan CEVP, OperationsExercise or conversion · — · 243 sh · 10b5-1 |
| Feb 11, 2026Form 4 | Meltzer Jonathan CEVP, OperationsExercise or conversion · Restricted Stock Unit · $0 · 243 sh · 10b5-1 |
| Feb 11, 2026Form 4 | Oyegunwa AkinboladeEVP, CIO & CTOExercise or conversion · — · 230 sh |
| Feb 11, 2026Form 4 | Oyegunwa AkinboladeEVP, CIO & CTOExercise or conversion · Restricted Stock Unit · $0 · 230 sh |
| Feb 11, 2026Form 4 | Summy Amy B.EVP, Chief Marketing OfficerExercise or conversion · — · 230 sh |
| Feb 11, 2026Form 4 | Summy Amy B.EVP, Chief Marketing OfficerExercise or conversion · Restricted Stock Unit · $0 · 230 sh |
| Feb 11, 2026Form 4 | Kyle Kathryn WEVP, Chief Legal OfficerExercise or conversion · — · 216 sh |
| Feb 11, 2026Form 4 | Kyle Kathryn WEVP, Chief Legal OfficerExercise or conversion · Restricted Stock Unit · $0 · 216 sh |
| Feb 10, 2026Form 4 | Schechter Adam HPresident & CEO · DirectorAward · Non-qualified Stock Options · $0 · 31,700 sh |
| Feb 10, 2026Form 4 | Schechter Adam HPresident & CEO · DirectorAward · Restricted Stock Unit · $0 · 10,440 sh |
| Feb 10, 2026Form 4 | Wang Julia AijunChief Financial Officer, EVPAward · Non-qualified Stock Options · $0 · 7,100 sh |
| Feb 10, 2026Form 4 | Caveney Brian JEVP, Pres of ED, CMO & CSOAward · Non-qualified Stock Options · $0 · 6,100 sh |
| Feb 10, 2026Form 4 | GRAHAM ANITA ZEVP, CHROAward · Non-qualified Stock Options · $0 · 4,100 sh |
| Feb 10, 2026Form 4 | Bailey Megan D.EVP, Pres, Central Labs & IntlAward · Non-qualified Stock Options · $0 · 3,300 sh |
| Feb 10, 2026Form 4 | Kyle Kathryn WEVP, Chief Legal OfficerAward · Non-qualified Stock Options · $0 · 2,700 sh |
| Feb 10, 2026Form 4 | Oyegunwa AkinboladeEVP, CIO & CTOAward · Non-qualified Stock Options · $0 · 2,400 sh |
| Feb 10, 2026Form 4 | Wang Julia AijunChief Financial Officer, EVPAward · Restricted Stock Unit · $0 · 2,350 sh |
| Feb 10, 2026Form 4 | Vaughn Bryan TEVP, DiagnosticsAward · Non-qualified Stock Options · $0 · 2,200 sh |
| Feb 10, 2026Form 4 | Caveney Brian JEVP, Pres of ED, CMO & CSOAward · Restricted Stock Unit · $0 · 2,020 sh |
| Feb 10, 2026Form 4 | Summy Amy B.EVP, Chief Marketing OfficerAward · Non-qualified Stock Options · $0 · 1,900 sh |
| Feb 10, 2026Form 4 | Meltzer Jonathan CEVP, OperationsAward · Non-qualified Stock Options · $0 · 1,900 sh · 10b5-1 |
| Feb 10, 2026Form 4 | GRAHAM ANITA ZEVP, CHROAward · Restricted Stock Unit · $0 · 1,360 sh |
| Feb 10, 2026Form 4 | Wilkinson Peter JSVP, Chief Accounting OfficerAward · Non-qualified Stock Options · $0 · 1,300 sh |
| Feb 10, 2026Form 4 | Bailey Megan D.EVP, Pres, Central Labs & IntlAward · Restricted Stock Unit · $0 · 1,100 sh |
| Feb 10, 2026Form 4 | Kyle Kathryn WEVP, Chief Legal OfficerAward · Restricted Stock Unit · $0 · 880 sh |
| Feb 10, 2026Form 4 | Oyegunwa AkinboladeEVP, CIO & CTOAward · Restricted Stock Unit · $0 · 810 sh |
| Feb 10, 2026Form 4 | ANDERSON KERRII BDirectorAward · Restricted Stock Unit · $0 · 773 sh |
| Feb 10, 2026Form 4 | Bulto Carulla VictorDirectorAward · Restricted Stock Unit · $0 · 773 sh |
| Feb 10, 2026Form 4 | Davis Jeffrey A.DirectorAward · Restricted Stock Unit · $0 · 773 sh |
| Feb 10, 2026Form 4 | Kliphouse Kirsten MarieDirectorAward · Restricted Stock Unit · $0 · 773 sh |
| Feb 10, 2026Form 4 | NEUPERT PETER MDirectorAward · Restricted Stock Unit · $0 · 773 sh |
| Feb 10, 2026Form 4 | Parham Richelle PDirectorAward · Restricted Stock Unit · $0 · 773 sh |
| Feb 10, 2026Form 4 | Wengel Kathryn EDirectorAward · Restricted Stock Unit · $0 · 773 sh |
| Feb 10, 2026Form 4 | Sampson John HDirectorAward · Restricted Stock Unit · $0 · 773 sh |
| Feb 10, 2026Form 4 | Kong GarhengDirectorAward · Restricted Stock Unit · $0 · 773 sh |
| Feb 10, 2026Form 4 | Rothman PaulDirectorAward · Restricted Stock Unit · $0 · 733 sh |
| Feb 10, 2026Form 4 | Vaughn Bryan TEVP, DiagnosticsAward · Restricted Stock Unit · $0 · 730 sh |
| Feb 10, 2026Form 4 | Summy Amy B.EVP, Chief Marketing OfficerAward · Restricted Stock Unit · $0 · 620 sh |
| Feb 10, 2026Form 4 | Meltzer Jonathan CEVP, OperationsAward · Restricted Stock Unit · $0 · 620 sh · 10b5-1 |
| Feb 10, 2026Form 4 | Wilkinson Peter JSVP, Chief Accounting OfficerAward · Restricted Stock Unit · $0 · 440 sh |
| Feb 9, 2026Form 4 | Schechter Adam HPresident & CEO · DirectorTax withholding · $370K · 1,352 sh |
| Feb 9, 2026Form 4 | Schroeder Mark SEVP, Pres Diagnostics & COOTax withholding · $60K · 219 sh |
| Feb 9, 2026Form 4 | Caveney Brian JEVP, Pres of ED, CMO & CSOTax withholding · $49K · 180 sh |
| Feb 9, 2026Form 4 | GRAHAM ANITA ZEVP, CHROTax withholding · $31K · 112 sh |
| Feb 9, 2026Form 4 | Bailey Megan D.EVP, Pres, Central Labs & IntlTax withholding · $30K · 108 sh |
| Feb 9, 2026Form 4 | van der Vaart Sandra DEVP, Corporate AffairsTax withholding · $25K · 93 sh |
| Feb 9, 2026Form 4 | Meltzer Jonathan CEVP, OperationsTax withholding · $22K · 82 sh · 10b5-1 |
| Feb 9, 2026Form 4 | Summy Amy B.EVP, Chief Marketing OfficerTax withholding · $22K · 80 sh |
| Feb 9, 2026Form 4 | Kyle Kathryn WEVP, Chief Legal OfficerTax withholding · $17K · 61 sh |
| Feb 9, 2026Form 4 | Vaughn Bryan TEVP, DiagnosticsTax withholding · $17K · 61 sh |
| Feb 9, 2026Form 4 | Oyegunwa AkinboladeEVP, CIO & CTOTax withholding · $14K · 51 sh |
| Feb 9, 2026Form 4 | Wilkinson Peter JSVP, Chief Accounting OfficerTax withholding · $13K · 46 sh |
| Feb 7, 2026Form 4 | Schechter Adam HPresident & CEO · DirectorExercise or conversion · — · 3,249 sh |
| Feb 7, 2026Form 4 | Schechter Adam HPresident & CEO · DirectorExercise or conversion · Restricted Stock Unit · $0 · 3,249 sh |
| Feb 7, 2026Form 4 | Schroeder Mark SEVP, Pres Diagnostics & COOExercise or conversion · — · 681 sh |
| Feb 7, 2026Form 4 | Schroeder Mark SEVP, Pres Diagnostics & COOExercise or conversion · Restricted Stock Unit · $0 · 681 sh |
| Feb 7, 2026Form 4 | Caveney Brian JEVP, Pres of ED, CMO & CSOExercise or conversion · — · 628 sh |
| Feb 7, 2026Form 4 | Caveney Brian JEVP, Pres of ED, CMO & CSOExercise or conversion · Restricted Stock Unit · $0 · 628 sh |
| Feb 7, 2026Form 4 | GRAHAM ANITA ZEVP, CHROExercise or conversion · — · 367 sh |
| Feb 7, 2026Form 4 | GRAHAM ANITA ZEVP, CHROExercise or conversion · Restricted Stock Unit · $0 · 367 sh |
| Feb 7, 2026Form 4 | van der Vaart Sandra DEVP, Corporate AffairsExercise or conversion · — · 353 sh |
| Feb 7, 2026Form 4 | van der Vaart Sandra DEVP, Corporate AffairsExercise or conversion · Restricted Stock Unit · $0 · 353 sh |
| Feb 7, 2026Form 4 | Bailey Megan D.EVP, Pres, Central Labs & IntlExercise or conversion · — · 289 sh |
| Feb 7, 2026Form 4 | Bailey Megan D.EVP, Pres, Central Labs & IntlExercise or conversion · Restricted Stock Unit · $0 · 289 sh |
| Feb 7, 2026Form 4 | Meltzer Jonathan CEVP, OperationsExercise or conversion · — · 263 sh · 10b5-1 |
| Feb 7, 2026Form 4 | Meltzer Jonathan CEVP, OperationsExercise or conversion · Restricted Stock Unit · $0 · 263 sh · 10b5-1 |
| Feb 7, 2026Form 4 | Summy Amy B.EVP, Chief Marketing OfficerExercise or conversion · — · 222 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 26 filings
| Filed | What it is |
|---|---|
| Sep 30, 20268-K | Labcorp to Announce Third Quarter Financial Results on October 28, 2026Regulation FD disclosure |
| Sep 22, 20268-K | Regulation FD disclosure |
| Sep 10, 20268-K | Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor DayRegulation FD disclosure |
| Aug 28, 20268-K | Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare ConferenceRegulation FD disclosure |
| Aug 17, 20268-K | Labcorp to Host Investor Day on September 10, 2026Regulation FD disclosure |
| Aug 14, 20268-K | Directors or officers; compensation |
| Aug 5, 202610-Q | Quarterly report, Q2 2026 — revenue $3.73B (+6% y/y), net income $298.7M, EPS $3.64 |
| Jul 30, 20268-K | Earnings release — EPS $4.99 vs $4.79 est. (+4.2%); revenue $3.73B (+6% y/y) 2.7% |
| Jul 10, 20268-K | Labcorp Declares Quarterly DividendRegulation FD disclosure |
| Jun 30, 20268-K | Labcorp to Announce Second Quarter Financial Results on July 30, 2026Regulation FD disclosure |
| May 27, 20268-K | Labcorp to Present at the Jefferies Global Healthcare ConferenceRegulation FD disclosure |
| May 26, 20268-K | Shareholder vote results |
| May 4, 202610-Q | Quarterly report, Q1 2026 — revenue $3.54B (+6% y/y), net income $277.8M, EPS $3.35 |
| Apr 30, 20268-K | Earnings release — EPS $4.25 vs $4.09 est. (+3.9%); revenue $3.54B (+6% y/y) 0.1% |
| Apr 10, 2026ARS | Annual report to shareholders |
| Apr 10, 2026DEFA14A | Additional proxy materials |
| Apr 10, 2026DEF 14A | Proxy statement |
| Apr 9, 20268-K | Labcorp Declares Quarterly DividendRegulation FD disclosure |
| Mar 31, 20268-K | Labcorp to Announce First Quarter Financial Results on April 30, 2026Regulation FD disclosure |
| Mar 20, 20268-K | Material definitive agreement; New financial obligation |
| Feb 24, 202610-K | Annual report, FY2025 — revenue $13.95B (+7% y/y), net income $876.5M, EPS $10.46 |
| Feb 17, 20268-K | Earnings release — EPS $4.07 vs $3.95 est. (+3.0%); revenue $3.52B (+6% y/y) 2.1% |
| Feb 9, 20268-K | Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of DirectorsDirectors or officers; compensation; Regulation FD disclosure |
| Jan 29, 20268-K | Material definitive agreement; New financial obligation |
| Jan 15, 20268-K | Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026Regulation FD disclosure |
| Jan 14, 20268-K | Labcorp Declares Quarterly DividendRegulation FD disclosure |
2025 · 29 filings
| Filed | What it is |
|---|---|
| Dec 30, 20258-K | Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare ConferenceRegulation FD disclosure |
| Dec 15, 20258-K | Directors or officers; compensation |
| Dec 10, 20258-K | Labcorp Announces Retirement of Dr. D. Gary Gilliland from its Board of DirectorsDirectors or officers; compensation; Regulation FD disclosure |
| Nov 24, 20258-K | Directors or officers; compensation; Regulation FD disclosure |
| Oct 31, 202510-Q | Quarterly report, Q3 2025 — revenue $3.56B (+9% y/y), net income $261.1M, EPS $3.12 |
| Oct 28, 20258-K | Earnings release — EPS $4.18 vs $4.13 est. (+1.2%); revenue $3.56B (+9% y/y) 5.8% |
| Oct 8, 20258-K | Labcorp Declares Quarterly DividendRegulation FD disclosure |
| Sep 25, 20258-K | Regulation FD disclosure |
| Aug 28, 20258-K | Regulation FD disclosure |
| Aug 1, 202510-Q | Quarterly report, Q2 2025 — revenue $3.53B (+10% y/y), net income $237.9M, EPS $2.84 |
| Jul 24, 20258-K | Earnings release — EPS $4.35 vs $4.14 est. (+5.1%); revenue $3.53B (+10% y/y) 6.9% |
| Jul 10, 20258-K | Regulation FD disclosure |
| Jun 27, 20258-K | Material definitive agreement; New financial obligation |
| Jun 26, 20258-K | Regulation FD disclosure |
| May 20, 20258-K | Directors or officers; compensation; Shareholder vote results |
| May 8, 20258-K | Regulation FD disclosure |
| Apr 29, 202510-Q | Quarterly report, Q1 2025 — revenue $3.35B (+5% y/y), net income $212.8M, EPS $2.52 |
| Apr 29, 20258-K | Earnings release — EPS $3.84 vs $3.73 est. (+3.0%); revenue $3.35B (+5% y/y) 4.7% |
| Apr 10, 20258-K | Regulation FD disclosure |
| Apr 4, 2025ARS | Annual report to shareholders |
| Apr 4, 2025DEFA14A | Additional proxy materials |
| Apr 4, 2025DEF 14A | Proxy statement |
| Mar 31, 20258-K | Regulation FD disclosure |
| Feb 25, 202510-K | Annual report, FY2024 — revenue $13.01B (+7% y/y), net income $746.0M, EPS $8.84 |
| Feb 6, 20258-K | Earnings release — EPS $3.45 vs $3.40 est. (+1.5%); revenue $3.33B (+10% y/y) 0.9% |
| Jan 31, 20258-K | Material definitive agreement; New financial obligation |
| Jan 10, 20258-K | Regulation FD disclosure |
| Jan 10, 20258-K | Regulation FD disclosure |
| Jan 8, 20258-K | Regulation FD disclosure |
2024 · 30 filings
| Filed | What it is |
|---|---|
| Nov 19, 20248-K | Directors or officers; compensation; Regulation FD disclosure |
| Oct 29, 202410-Q | Quarterly report, Q3 2024 — revenue $3.28B (+7% y/y), net income $169.3M, EPS $2.00 |
| Oct 24, 20248-K | Earnings release — EPS $3.50 vs $3.48 est. (+0.6%); revenue $3.28B (+7% y/y) 4.6% |
| Oct 10, 20248-K | Regulation FD disclosure |
| Sep 24, 20248-K | Regulation FD disclosure |
| Sep 23, 20248-K | Material definitive agreement |
| Sep 18, 20248-K | Other events |
| Sep 3, 20248-K | Regulation FD disclosure |
| Aug 23, 20248-K | Material definitive agreement; New financial obligation |
| Aug 2, 202410-Q | Quarterly report, Q2 2024 — revenue $3.22B, net income $205.3M, EPS $2.43 |
| Aug 1, 20248-K | Earnings release — EPS $3.94 vs $3.78 est. (+4.2%); revenue $3.22B 8.3% |
| Jul 25, 20248-K | Regulation FD disclosure |
| Jul 1, 20248-K | Regulation FD disclosure |
| Jun 4, 20248-K | Regulation FD disclosure |
| May 28, 20248-K | Regulation FD disclosure |
| May 16, 20248-K | Shareholder vote results |
| May 8, 20248-K | Regulation FD disclosure |
| May 6, 2024PX14A6G | Shareholder exempt solicitation |
| Apr 30, 202410-Q | Quarterly report, Q1 2024 — revenue $3.18B (+5% y/y), net income $228.0M, EPS $2.69 |
| Apr 25, 20248-K | Earnings release — EPS $3.68 vs $3.46 est. (+6.4%); revenue $3.18B (+5% y/y) 4.6% |
| Apr 11, 20248-K | Regulation FD disclosure |
| Apr 4, 2024ARS | Annual report to shareholders |
| Apr 4, 2024DEFA14A | Additional proxy materials |
| Apr 4, 2024DEF 14A | Proxy statement |
| Mar 27, 20248-K | Regulation FD disclosure |
| Feb 26, 202410-K | Annual report, FY2023 — revenue $12.16B (+3% y/y), net income $418.0M, EPS $4.77 |
| Feb 15, 20248-K | Earnings release — EPS $3.30 vs $3.29 est. (+0.3%); revenue $3.03B (−48% y/y) 2.6% |
| Jan 16, 20248-K | Regulation FD disclosure |
| Jan 12, 20248-K | Regulation FD disclosure |
| Jan 2, 20248-K | Regulation FD disclosure |
2023 · 39 filings — 27 × 8-K, 3 × 10-Q, 3 × 8-K/A and 5 other forms
| Filed | What it is |
|---|---|
| Oct 30, 202310-Q | Quarterly report, Q3 2023 — revenue $3.06B (−22% y/y), net income $183.3M |
| Aug 4, 202310-Q | Quarterly report |
| May 4, 202310-Q | Quarterly report, Q1 2023 — revenue $3.04B, net income $212.9M, EPS $2.39 |
| May 2, 2023DEFA14A | Additional proxy materials |
| Apr 4, 2023PX14A6G | Shareholder exempt solicitation |
| Mar 30, 2023ARS | Annual report to shareholders |
| Mar 30, 2023DEFA14A | Additional proxy materials |
| Mar 30, 2023DEF 14A | Proxy statement |
| Feb 28, 202310-K | Annual report, FY2022 — revenue $11.86B (−10% y/y), net income $1.28B, EPS $13.97 |
30 current reports (8-K) not listed; the year is on EDGAR.
2022 · 26 filings — 20 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 1, 202210-Q | Quarterly report |
| Aug 1, 202210-Q | Quarterly report, Q2 2022 — revenue $2.92B (−24% y/y), net income $358.6M |
| Apr 29, 202210-Q | Quarterly report, Q3 2022 — revenue $3.90B (−4% y/y), net income $491.6M |
| Mar 31, 2022DEFA14A | Additional proxy materials |
| Mar 31, 2022DEF 14A | Proxy statement |
| Feb 25, 202210-K | Annual report, FY2021 — revenue $13.14B (−6% y/y), net income $2.38B, EPS $24.39 |
20 current reports (8-K) not listed; the year is on EDGAR.
2021 · 32 filings — 24 × 8-K, 3 × 10-Q, 2 × 8-K/A and 3 other forms
| Filed | What it is |
|---|---|
| Nov 2, 202110-Q | Quarterly report, Q3 2021 — revenue $4.06B (+4% y/y), net income $587.3M, EPS $6.05 |
| Aug 5, 202110-Q | Quarterly report, Q2 2021 — revenue $3.84B (+39% y/y), net income $467.4M, EPS $4.76 |
| May 4, 202110-Q | Quarterly report, Q1 2021 — revenue $4.16B (+47% y/y), net income $769.6M, EPS $7.82 |
| Apr 2, 2021DEFA14A | Additional proxy materials |
| Apr 2, 2021DEF 14A | Proxy statement |
| Feb 25, 202110-K | Annual report, FY2020 — revenue $13.98B (+21% y/y), net income $1.56B, EPS $15.88 |
26 current reports (8-K) not listed; the year is on EDGAR.
2020 · 27 filings — 20 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Oct 29, 202010-Q | Quarterly report, Q3 2020 — revenue $3.90B (+33% y/y), net income $703.4M, EPS $7.17 |
| Jul 31, 202010-Q | Quarterly report, Q2 2020 — revenue $2.77B (−4% y/y), net income $231.6M, EPS $2.37 |
| May 8, 202010-Q | Quarterly report, Q1 2020 — revenue $2.82B (+1% y/y), net income −$317.2M, EPS −$3.27 |
| Apr 1, 2020DEFA14A | Additional proxy materials |
| Apr 1, 2020DEF 14A | Proxy statement |
| Mar 5, 202010-K/A | Annual report, amended |
| Feb 28, 202010-K | Annual report, FY2019 — revenue $11.55B (+2% y/y), net income $823.8M, EPS $8.35 |
20 current reports (8-K) not listed; the year is on EDGAR.
2019 · 53 filings — 45 × 8-K, 3 × 10-Q, 2 × 8-K/A and 3 other forms
| Filed | What it is |
|---|---|
| Oct 31, 201910-Q | Quarterly report, Q3 2019 — revenue $2.93B (+3% y/y), net income −$317.2M, EPS $2.25 |
| Aug 8, 201910-Q | Quarterly report, Q2 2019 — revenue $2.88B (+1% y/y), net income $190.4M, EPS $1.93 |
| May 3, 201910-Q | Quarterly report, Q1 2019 — revenue $2.79B (−2% y/y), net income $185.6M, EPS $1.86 |
| Mar 29, 2019DEFA14A | Additional proxy materials |
| Mar 29, 2019DEF 14A | Proxy statement |
| Feb 28, 201910-K | Annual report, FY2018 — revenue $11.33B (+10% y/y), net income $883.7M, EPS $8.61 |
47 current reports (8-K) not listed; the year is on EDGAR.
2018 · 68 filings — 60 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms
| Filed | What it is |
|---|---|
| Oct 30, 201810-Q | Quarterly report, Q3 2018 — revenue $2.83B (+8% y/y), net income $318.8M, EPS $3.10 |
| Jul 27, 201810-Q | Quarterly report, Q2 2018 — revenue $2.87B (+13% y/y), net income $233.8M, EPS $2.27 |
| May 1, 201810-Q | Quarterly report, Q1 2018 — revenue $2.85B (+18% y/y), net income $173.2M, EPS $1.67 |
| Apr 6, 2018DEFA14A | Additional proxy materials |
| Mar 30, 2018DEFA14A | Additional proxy materials |
| Mar 30, 2018DEF 14A | Proxy statement |
| Feb 27, 201810-K | Annual report, FY2017 — revenue $10.31B (+8% y/y), net income $1.23B, EPS $11.81 |
61 current reports (8-K) not listed; the year is on EDGAR.
2017 · 66 filings — 60 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 2, 201710-Q | Quarterly report, Q3 2017 — revenue $2.62B (+9% y/y), net income $171.5M, EPS $1.65 |
| Aug 2, 201710-Q | Quarterly report, Q2 2017 — revenue $2.53B (+4% y/y), net income $184.8M, EPS $1.78 |
| Apr 28, 201710-Q | Quarterly report, Q1 2017 — revenue $2.41B (−75% y/y), net income $183.0M, EPS $1.75 |
| Mar 31, 2017DEFA14A | Additional proxy materials |
| Mar 31, 2017DEF 14A | Proxy statement |
| Feb 27, 201710-K | Annual report, FY2016 — revenue $9.55B (+10% y/y), net income $711.8M, EPS $6.82 |
60 current reports (8-K) not listed; the year is on EDGAR.
2016 · 58 filings — 51 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2015 · 66 filings — 56 × 8-K, 3 × 10-Q, 2 × 8-K/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2014 · 48 filings — 42 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2013 · 50 filings — 43 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2012 · 48 filings — 39 × 8-K, 3 × 10-Q, 2 × DEFA14A and 4 other forms
Counted, not listed; the year is on EDGAR.
2011 · 48 filings — 41 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2010 · 60 filings — 52 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
Counted, not listed; the year is on EDGAR.
2009 · 44 filings — 34 × 8-K, 3 × 10-Q, 2 × 8-K/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2008 · 57 filings — 51 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2007 · 47 filings — 42 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2006 · 42 filings — 35 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2005 · 45 filings — 38 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2004 · 35 filings — 28 × 8-K, 3 × 10-Q, 2 × 8-K/A and 2 other forms
Counted, not listed; the year is on EDGAR.
2003 · 44 filings — 35 × 8-K, 3 × 10-Q, 3 × 8-K/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2002 · 63 filings — 45 × 8-K, 6 × DEFR14A, 3 × 10-Q and 5 other forms
Counted, not listed; the year is on EDGAR.
2001 · 41 filings — 34 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2000 · 37 filings — 30 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
1999 · 30 filings — 24 × 8-K, 3 × 10-Q, 1 × 10-K405 and 2 other forms
Counted, not listed; the year is on EDGAR.
1998 · 25 filings — 18 × 8-K, 3 × 10-Q, 1 × 10-K405 and 3 other forms
Counted, not listed; the year is on EDGAR.
1997 · 21 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K405 and 4 other forms
Counted, not listed; the year is on EDGAR.
1996 · 13 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K405 and 1 other form
Counted, not listed; the year is on EDGAR.
1995 · 10 filings — 4 × 8-K, 3 × 10-Q, 1 × 10-K405 and 2 other forms
Counted, not listed; the year is on EDGAR.
1994 · 4 filings — 2 × 10-Q, 2 × 8-K
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 107 filings — 83 × 4, 17 × 144, 4 × 3 and 3 other forms
| Filed | What it is |
|---|---|
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Aug 18, 20264 | Insider transaction (Form 4) |
| Aug 17, 2026144 | Notice of proposed sale (Form 144) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 11, 2026144 | Notice of proposed sale (Form 144) |
| Aug 6, 20264 | Insider transaction (Form 4) |
| Aug 5, 20264 | Insider transaction (Form 4) |
| Aug 4, 2026144 | Notice of proposed sale (Form 144) |
| Jul 6, 20264 | Insider transaction (Form 4) |
| Jul 6, 20264 | Insider transaction (Form 4) |
| Jul 2, 2026144 | Notice of proposed sale (Form 144) |
| Jul 2, 2026144 | Notice of proposed sale (Form 144) |
| Jul 1, 2026144 | Notice of proposed sale (Form 144) |
| Jun 10, 20264 | Insider transaction (Form 4) |
| Jun 8, 2026144 | Notice of proposed sale (Form 144) |
| May 22, 2026SD | Specialized disclosure (conflict minerals) |
| May 13, 20264 | Insider transaction (Form 4) |
| May 11, 2026144 | Notice of proposed sale (Form 144) |
| May 6, 2026144 | Notice of proposed sale (Form 144) |
| Apr 28, 2026SCHEDULE 13G | Other filings |
| Mar 30, 20264 | Insider transaction (Form 4) |
| Mar 30, 20264 | Insider transaction (Form 4) |
The newest 25 of 107 shown; the full year is on EDGAR.
2025 · 99 filings — 75 × 4, 19 × 144, 1 × 3 and 4 other forms
| Filed | What it is |
|---|---|
| Dec 3, 20254 | Insider transaction (Form 4) |
| Dec 3, 20253 | Initial insider holdings (Form 3) |
| Nov 13, 20254 | Insider transaction (Form 4) |
| Nov 12, 2025144 | Notice of proposed sale (Form 144) |
| Nov 4, 20254 | Insider transaction (Form 4) |
| Nov 4, 20254 | Insider transaction (Form 4) |
| Nov 4, 20254 | Insider transaction (Form 4) |
| Oct 31, 2025144 | Notice of proposed sale (Form 144) |
| Aug 15, 20254 | Insider transaction (Form 4) |
| Aug 13, 2025144 | Notice of proposed sale (Form 144) |
| Aug 13, 20254 | Insider transaction (Form 4) |
| Aug 11, 2025144 | Notice of proposed sale (Form 144) |
| Aug 1, 20254 | Insider transaction (Form 4) |
| Jul 31, 20254 | Insider transaction (Form 4) |
| Jul 30, 2025144 | Notice of proposed sale (Form 144) |
| Jul 28, 20254 | Insider transaction (Form 4) |
| Jul 28, 20254 | Insider transaction (Form 4) |
| Jul 24, 2025144 | Notice of proposed sale (Form 144) |
| Jul 2, 20254 | Insider transaction (Form 4) |
| Jun 12, 20254 | Insider transaction (Form 4) |
| Jun 11, 2025144 | Notice of proposed sale (Form 144) |
| Jun 5, 20254 | Insider transaction (Form 4) |
| Jun 3, 2025144 | Notice of proposed sale (Form 144) |
| May 30, 2025SD | Specialized disclosure (conflict minerals) |
| May 29, 2025S-8 | Employee stock plan registration |
The newest 25 of 99 shown; the full year is on EDGAR.
2024 · 135 filings — 77 × 4, 25 × 144, 17 × S-8 POS and 12 other forms
| Filed | What it is |
|---|---|
| Dec 4, 20244 | Insider transaction (Form 4) |
| Dec 4, 20244 | Insider transaction (Form 4) |
| Dec 4, 20244 | Insider transaction (Form 4) |
| Dec 3, 20243 | Initial insider holdings (Form 3) |
| Dec 2, 2024144 | Notice of proposed sale (Form 144) |
| Dec 2, 2024144 | Notice of proposed sale (Form 144) |
| Nov 26, 20244 | Insider transaction (Form 4) |
| Nov 25, 20244 | Insider transaction (Form 4) |
| Nov 22, 2024144 | Notice of proposed sale (Form 144) |
| Nov 21, 2024144 | Notice of proposed sale (Form 144) |
| Nov 13, 20244 | Insider transaction (Form 4) |
| Nov 12, 2024144 | Notice of proposed sale (Form 144) |
| Nov 5, 20244 | Insider transaction (Form 4) |
| Nov 5, 20244 | Insider transaction (Form 4) |
| Nov 4, 20243 | Initial insider holdings (Form 3) |
| Oct 25, 20244 | Insider transaction (Form 4) |
| Oct 24, 2024144 | Notice of proposed sale (Form 144) |
| Oct 18, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Sep 18, 2024424B5 | Prospectus supplement |
| Sep 16, 2024FWP | Free writing prospectus |
| Sep 16, 2024424B5 | Prospectus supplement |
| Sep 3, 2024144/A | Notice of proposed sale (Form 144), amended |
| Sep 3, 2024144 | Notice of proposed sale (Form 144) |
| Aug 21, 20244 | Insider transaction (Form 4) |
| Aug 19, 2024144 | Notice of proposed sale (Form 144) |
The newest 25 of 135 shown; the full year is on EDGAR.
2023 · 112 filings — 97 × 4, 6 × 3, 4 × SC 13G/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2022 · 81 filings — 74 × 4, 3 × SC 13G/A, 1 × 3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2021 · 73 filings — 65 × 4, 2 × 424B5, 2 × SC 13G/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2020 · 70 filings — 65 × 4, 2 × SC 13G/A, 1 × 3 and 2 other forms
Counted, not listed; the year is on EDGAR.
2019 · 73 filings — 58 × 4, 6 × 3, 4 × SC 13G/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2018 · 76 filings — 71 × 4, 2 × SC 13G/A, 1 × 5 and 2 other forms
Counted, not listed; the year is on EDGAR.
2017 · 82 filings — 66 × 4, 4 × SC 13G/A, 3 × UPLOAD and 6 other forms
Counted, not listed; the year is on EDGAR.
2016 · 79 filings — 58 × 4, 6 × SC TO-T/A, 5 × 3 and 5 other forms
Counted, not listed; the year is on EDGAR.
2015 · 88 filings — 61 × 4, 6 × 425, 5 × SC 13G/A and 11 other forms
Counted, not listed; the year is on EDGAR.
2014 · 83 filings — 56 × 4, 11 × 425, 4 × 3 and 9 other forms
Counted, not listed; the year is on EDGAR.
2013 · 78 filings — 62 × 4, 3 × 3, 3 × SC 13G/A and 6 other forms
Counted, not listed; the year is on EDGAR.
2012 · 67 filings — 54 × 4, 4 × SC 13G/A, 2 × 424B5 and 5 other forms
Counted, not listed; the year is on EDGAR.
2011 · 73 filings — 44 × 4, 16 × SC TO-T/A, 2 × 3 and 9 other forms
Counted, not listed; the year is on EDGAR.
2010 · 66 filings — 54 × 4, 3 × SC 13G/A, 2 × 4/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2009 · 65 filings — 43 × 4, 6 × 3, 5 × SC TO-T/A and 6 other forms
Counted, not listed; the year is on EDGAR.
2008 · 141 filings — 128 × 4, 2 × 4/A, 2 × 5 and 7 other forms
Counted, not listed; the year is on EDGAR.
2007 · 188 filings — 174 × 4, 5 × 3, 3 × 4/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2006 · 168 filings — 148 × 4, 3 × SC TO-I/A, 3 × UPLOAD and 11 other forms
Counted, not listed; the year is on EDGAR.
2005 · 141 filings — 131 × 4, 3 × 424B5, 2 × 3 and 5 other forms
Counted, not listed; the year is on EDGAR.
2004 · 158 filings — 148 × 4, 4 × 3, 3 × SC 13G/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2003 · 124 filings — 101 × 4, 12 × 5, 3 × 4/A and 8 other forms
Counted, not listed; the year is on EDGAR.
2002 · 60 filings — 25 × 4, 20 × 424B3, 3 × S-3/A and 8 other forms
Counted, not listed; the year is on EDGAR.
2001 · 10 filings — 3 × S-3/A, 2 × S-3, 2 × SC 13D/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2000 · 18 filings — 4 × 424B2, 3 × S-8, 3 × SC 13D/A and 5 other forms
Counted, not listed; the year is on EDGAR.
1999 · 5 filings — 4 × SC 13G, 1 × SC 13G/A
Counted, not listed; the year is on EDGAR.
1998 · 2 filings — 2 × SC 13G/A
Counted, not listed; the year is on EDGAR.
1997 · 13 filings — 3 × S-3/A, 2 × 8-A12B, 2 × S-8 and 6 other forms
Counted, not listed; the year is on EDGAR.
1996 · 3 filings — 2 × SC 13G/A, 1 × S-8
Counted, not listed; the year is on EDGAR.
1995 · 13 filings — 3 × SC 13G/A, 2 × S-4, 2 × SC 13G and 6 other forms
Counted, not listed; the year is on EDGAR.
1994 · 7 filings — 2 × S-8 POS, 1 × 424B3, 1 × 8-B12B and 3 other forms
Counted, not listed; the year is on EDGAR.
About this data#
Labcorp Holdings Inc. (LH) has 3,890 filings on EDGAR going back to 1994: 39 annual reports, 100 quarterly reports and 1,110 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Sep 30, 2026, furnished a press release headed “Labcorp to Announce Third Quarter Financial Results on October 28, 2026”. Over the last 13 months insiders sold $10.4M in 18 sales and bought nothing on the open market; 198 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Labcorp Holdings Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read LH's latest 10-K?
- LH's latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did LH last file an 8-K?
- On Sep 30, 2026 it furnished a press release headed “Labcorp to Announce Third Quarter Financial Results on October 28, 2026”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Jul 30, 2026.
- Are LH insiders buying or selling?
- Over the last 13 months insiders sold $10.4M in 18 sales and bought nothing on the open market; 198 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: ANDERSON KERRII B (Director) sold 3,000 shares on Aug 17, 2026 for $954K, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has LH made?
- 3,890 filings are on EDGAR under the registrant records that have been Labcorp Holdings Inc., going back to 1994; 2,180 of them are insider ownership forms (Forms 3, 4, 5 and 144).